166 related articles for article (PubMed ID: 17506590)
1. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.
Pan CY; Landen H
Clin Drug Investig; 2007; 27(6):397-405. PubMed ID: 17506590
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus.
Hung YJ; Kuo SW; Wang CH; Chang HY; Hsieh SH; Landen H
Clin Drug Investig; 2006; 26(10):559-65. PubMed ID: 17163289
[TBL] [Abstract][Full Text] [Related]
3. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
[TBL] [Abstract][Full Text] [Related]
4. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
6. A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study.
Zhang W; Kim D; Philip E; Miyan Z; Barykina I; Schmidt B; Stein H;
Clin Drug Investig; 2013 Apr; 33(4):263-74. PubMed ID: 23435929
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.
Mertes G
Diabetes Res Clin Pract; 2001 Jun; 52(3):193-204. PubMed ID: 11323089
[TBL] [Abstract][Full Text] [Related]
8. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
Hanefeld M; Schaper F
Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
[TBL] [Abstract][Full Text] [Related]
9. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus.
Li C; Hung YJ; Qamruddin K; Aziz MF; Stein H; Schmidt B
Diabetes Res Clin Pract; 2011 Apr; 92(1):57-64. PubMed ID: 21251726
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance.
Pan CY; Gao Y; Chen JW; Luo BY; Fu ZZ; Lu JM; Guo XH; Cheng H
Diabetes Res Clin Pract; 2003 Sep; 61(3):183-90. PubMed ID: 12965108
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Fogari E; Salvadeo SA; Ferrari I; Gravina A; Fassi R; Fogari R
Clin Drug Investig; 2006; 26(9):529-39. PubMed ID: 17163286
[TBL] [Abstract][Full Text] [Related]
13. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Luis Bautista J; Bugos C; Dirnberger G; Atherton T
Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
[TBL] [Abstract][Full Text] [Related]
16. Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy.
Bachmann W; Petzinna D; Raptis SA; Wascher T; Westermeier T;
Clin Drug Investig; 2003; 23(10):679-86. PubMed ID: 17535083
[TBL] [Abstract][Full Text] [Related]
17. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
[TBL] [Abstract][Full Text] [Related]
18. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
20. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
